On the human remains from the medieval fortification of Tver Kremlin (Russia)

We report the human bones, found during the excavations near the medieval fortification (12th – 13th cent.) of Tver Kremlin. Comparison with several medieval cities of Russia suggests that bones belong to the people, who defended the stronghold against Mongols in 1238

Target-Speaker Voice Activity Detection: a Novel Approach for Multi-Speaker Diarization in a Dinner Party Scenario

Speaker diarization for real-life scenarios is an extremely challenging problem. Widely used clustering-based diarization approaches perform rather poorly in such conditions, mainly due to the limited ability to handle overlapping speech. We propose a novel Target-Speaker Voice Activity Detection (TS-VAD) approach, which directly predicts an activity of each speaker on each time frame. TS-VAD model takes conventional speech features (e.g., MFCC) along with i-vectors for each speaker as inputs. A set of binary classification output layers produces activities of each speaker. I-vectors can be estimated iteratively, starting with a strong clustering-based diarization. We also extend the TS-VAD approach to the multi-microphone case using a simple attention mechanism on top of hidden representations extracted from the single-channel TS-VAD model. Moreover, post-processing strategies for the predicted speaker activity probabilities are investigated. Experiments on the CHiME-6 unsegmented data show that TS-VAD achieves state-of-the-art results outperforming the baseline x-vector-based system by more than 30% Diarization Error Rate (DER) abs.Comment: Accepted to Interspeech 202

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Problèmes psychologiques de l'émigration

La littérature existante autour de la question de l'émigration juive d'URSS en Israël porte sur deux groupes d'émigrants distinctifs provenant pourtant de la même culture : ceux qui sont économiquement motivés et déterminés de trouver une situation en Israël et ceux qui, ayant de sérieux problèmes et sans but concret, partent à la recherche d'un Eldorado. Les premiers savent où ils vont et pourquoi, les seconds ont pour seul objectif de quitter le pays : c'est l'émigration proprement dite. Au..

Results of engine tests of an experimental gasoline internal combustion engine

To improve the power and fuel and economic performance of a gasoline internal combustion engine, it has been proposed to improve the insulating properties of the piston by forming a heat-insulating coating on the working surfaces of the piston head with a thickness of 25...30 μm using the microarc oxidation method. Comparative results of engine tests are carried out, which showed that an engine equipped with pistons with a heat-insulating coating on the working surfaces of the head increases power by 5.3 % and reduces hourly fuel consumption by 5.7 % compared to an engine equipped with standard pistons

The current stage of development of the receiving complex of the millimetron space observatory

We present an overview of the state of the onboard receiving complex of the Millimetron space observatory in the development phase of its preliminary design. The basic parameters of the onboard equipment planned to create and required for astrophysical observations are considered. A review of coherent and incoherent detectors, which are central to each receiver of the observatory, is given. Their characteristics and limiting parameters feasible at the present level of technology are reported

Vers un ailleurs prometteur…

Les migrations sont-elles une réponse universelle à une situation de crise ? Poser cette question ouvre sans doute le plus vaste débat sur l’histoire du mouvement des hommes. Cet ouvrage illustre bien la diversité et la multiplicité de cette incroyable richesse qu'est le mouvement des hommes et des peuples sur notre planète. Tout changement est un déséquilibre et, réciproquement, ce sont les déséquilibres qui permettent le changement. Est-il possible d’anticiper, dès lors, sur le futur ? Peut-on imaginer ce que sera demain la grande mouvance des peuples ? Engendrera-t-elle autant de peurs que d’innovations ? Comme le prévisage Albert Jacquard, les migrations de masse sont des catastrophes. Ainsi, “préparer demain”, nécessite des changements fondamentaux dans nos “visions du monde” politiques, économiques et sociales tout autant que dans notre mode d’exploitation des ressources naturelles.HERMANN-MICHEL HAGMANN Secrétaire général Laboratoire de démographie économique et sociale Université de Genève JEAN-LUC MAURER Directeur Institut universitaire d'études du développement Genèv

Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo